| 1720- | Lyco, | Antioxidant and Pro-oxidant Activities of Carotenoids |
| - | Review, | Nor, | NA |
| 1719- | Lyco, | Lycopene for the prevention and treatment of prostate disease. |
| - | Review, | Var, | NA |
| 1718- | Lyco, | The role of carotenoids in the prevention of human pathologies |
| - | Review, | Var, | NA |
| 1717- | Lyco, | Potential Role of Carotenoids as Antioxidants in Human Health and Disease |
| - | Review, | Var, | NA |
| 1716- | Lyco, | Anti-inflammatory Activity of β-Carotene, Lycopene and Tri-n-butylborane, a Scavenger of Reactive Oxygen Species |
| - | in-vitro, | AML, | RAW264.7 |
| 2545- | M-Blu, | Reversing the Warburg Effect as a Treatment for Glioblastoma |
| - | in-vitro, | GBM, | U87MG | - | NA, | AD, | NA | - | in-vitro, | GBM, | A172 | - | in-vitro, | GBM, | T98G |
| 2546- | M-Blu, | SDT, | The sonodynamic antitumor effect of methylene blue on sarcoma180 cells in vitro |
| - | in-vitro, | sarcoma, | S180 |
| 2544- | M-Blu, | Methylene blue and its importance in medicine |
| - | Review, | NA, | NA |
| 2543- | M-Blu, | The use of methylene blue to control the tumor oxygenation level |
| - | in-vivo, | Lung, | NA |
| 2542- | M-Blu, | In Vitro Methylene Blue and Carboplatin Combination Triggers Ovarian Cancer Cells Death |
| - | in-vitro, | Ovarian, | OV1369 | - | in-vitro, | Ovarian, | OV1946 | - | in-vitro, | Nor, | ARPE-19 |
| 2541- | M-Blu, | Spectroscopic Study of Methylene Blue Interaction with Coenzymes and its Effect on Tumor Metabolism |
| - | in-vivo, | Var, | NA |
| 2540- | M-Blu, | Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 2547- | M-Blu, | SDT, | The effect of dual-frequency ultrasound waves on B16F10 melanoma cells: Sonodynamic therapy using nanoliposomes containing methylene blue |
| - | in-vitro, | Melanoma, | B16-BL6 |
| 2535- | M-Blu, | SDT, | Apoptosis of ovarian cancer cells induced by methylene blue-mediated sonodynamic action |
| - | in-vitro, | Ovarian, | HO-8910 |
| 2534- | M-Blu, | doxoR, | PDT, | Methylene Blue-Mediated Photodynamic Therapy in Combination With Doxorubicin: A Novel Approach in the Treatment of HT-29 Colon Cancer Cells |
| - | in-vitro, | CRC, | HT-29 |
| 2533- | M-Blu, | PDT, | Methylene blue-mediated photodynamic therapy enhances apoptosis in lung cancer cells |
| - | in-vitro, | Lung, | A549 |
| 2532- | M-Blu, | PDT, | Methylene blue in anticancer photodynamic therapy: systematic review of preclinical studies |
| - | Review, | Var, | NA |
| 2531- | M-Blu, | Anticancer activity of methylene blue via inhibition of heat shock protein 70 |
| - | in-vitro, | Lung, | A549 | - | in-vivo, | NA, | NA |
| 1196- | MAG, | 2-O-Methylmagnolol, a Magnolol Derivative, Suppresses Hepatocellular Carcinoma Progression via Inhibiting Class I Histone Deacetylase Expression |
| - | in-vitro, | HCC, | NA |
| 1197- | MAG, | Magnolol as STAT3 inhibitor for treating multiple sclerosis by restricting Th17 cells |
| - | in-vivo, | MS, | NA |
| 1198- | MAG, | Mitochondria-targeted magnolol inhibits OXPHOS, proliferation, and tumor growth via modulation of energetics and autophagy in melanoma cells |
| - | in-vivo, | Melanoma, | NA |
| 1314- | MAG, | Magnolol induces apoptosis via activation of both mitochondrial and death receptor pathways in A375-S2 cells |
| - | in-vitro, | Melanoma, | A375 |
| 5252- | MAG, | Insights on the Multifunctional Activities of Magnolol |
| - | Review, | Var, | NA |
| 4534- | MAG, | Molecular mechanisms of apoptosis induced by magnolol in colon and liver cancer cells |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | CRC, | COLO205 |
| 4518- | MAG, | Cisplatin, | Evaluating the Magnolol Anticancer Potential in MKN-45 Gastric Cancer Cells |
| - | in-vitro, | GC, | MKN45 |
| 4514- | MAG, | Magnolol and its semi-synthetic derivatives: a comprehensive review of anti-cancer mechanisms, pharmacokinetics, and future therapeutic potential |
| - | Review, | Var, | NA |
| 4515- | MAG, | Magnolol as a Potential Anticancer Agent: A Proposed Mechanistic Insight |
| - | Review, | Var, | NA |
| 4516- | MAG, | Magnolol Induces Apoptosis and Suppresses Immune Evasion in Non-small Cell Lung Cancer Xenograft Models |
| - | in-vivo, | NSCLC, | NA |
| 4528- | MAG, | Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update |
| - | Review, | Nor, | NA |
| 4535- | MAG, | 5-FU, | Magnolol and 5-fluorouracil synergy inhibition of metastasis of cervical cancer cells by targeting PI3K/AKT/mTOR and EMT pathways |
| - | in-vitro, | Cerv, | NA |
| 4536- | MAG, | Magnolol suppresses proliferation of cultured human colon and liver cancer cells by inhibiting DNA synthesis and activating apoptosis |
| - | in-vitro, | Liver, | HepG2 | - | in-vivo, | CRC, | COLO205 |
| 4537- | MAG, | Effects of magnolol on UVB-induced skin cancer development in mice and its possible mechanism of action |
| - | in-vivo, | Melanoma, | NA | - | in-vitro, | Melanoma, | A431 |
| 4533- | MAG, | Magnolol, a natural compound, induces apoptosis of SGC-7901 human gastric adenocarcinoma cells via the mitochondrial and PI3K/Akt signaling pathways |
| - | in-vitro, | GC, | SGC-7901 |
| 4532- | MAG, | Cisplatin, | Magnolol Attenuates Cisplatin-Induced Muscle Wasting by M2c Macrophage Activation |
| - | in-vivo, | Var, | NA |
| 4531- | MAG, | Magnolol-induced apoptosis in HCT-116 colon cancer cells is associated with the AMP-activated protein kinase signaling pathway |
| - | in-vitro, | CRC, | HCT116 |
| 4530- | MAG, | Magnolol inhibits cancer stemness and IL-6/Stat3 signaling in oral carcinomas |
| - | in-vitro, | Oral, | NA |
| 4529- | MAG, | Effectiveness of Magnolol, a Lignan from Magnolia Bark, in Diabetes, Its Complications and Comorbidities—A Review |
| - | Review, | Diabetic, | NA |
| 4517- | MAG, | Mitochondrion-targeted magnolol derivatives exert synergistic anticancer activity by modulating energy metabolism and tumor microenvironment |
| - | vitro+vivo, | Var, | NA |
| 4527- | MAG, | Magnolol inhibits growth and induces apoptosis in esophagus cancer KYSE-150 cell lines via the MAP kinase pathway |
| - | in-vitro, | ESCC, | TE1 | - | in-vitro, | ESCC, | Eca109 | - | vitro+vivo, | SCC, | KYSE150 |
| 4526- | MAG, | HNK, | Targeting apoptosis pathways in cancer with magnolol and honokiol, bioactive constituents of the bark of Magnolia officinalis |
| - | Review, | Var, | NA |
| 4525- | MAG, | HNK, | Magnolol and Honokiol: Two Natural Compounds with Similar Chemical Structure but Different Physicochemical and Stability Properties |
| - | Study, | Nor, | NA |
| 4524- | MAG, | Magnolol facilitates mitochondrial-peroxisome dysfunction and induces oxeiptosis in lung cancer cells following transfer via tunneling nanotubes |
| - | vitro+vivo, | Lung, | NA |
| 4521- | MAG, | HNK, | Safety and Toxicology of Magnolol and Honokiol |
| - | Review, | Nor, | NA |
| 4520- | MAG, | Magnolol Suppresses Pancreatic Cancer Development In Vivo and In Vitro via Negatively Regulating TGF-β/Smad Signaling |
| - | vitro+vivo, | PC, | PANC1 |
| 4519- | MAG, | Magnolol: A Neolignan from the Magnolia Family for the Prevention and Treatment of Cancer |
| - | Review, | Var, | NA |
| 1089- | MAG, | Magnolol potently suppressed lipopolysaccharide-induced iNOS and COX-2 expression via downregulating MAPK and NF-κB signaling pathways |
| - | in-vitro, | AML, | RAW264.7 |
| 972- | MAG, | Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells |
| - | vitro+vivo, | Bladder, | T24/HTB-9 |
| 2450- | Matr, | The Promoting Role of HK II in Tumor Development and the Research Progress of Its Inhibitors |
| - | Review, | Var, | NA |
| 2643- | MCT, | Medium Chain Triglycerides enhances exercise endurance through the increased mitochondrial biogenesis and metabolism |
| - | Review, | Nor, | NA |
| 2644- | MCT, | The Effects of Medium-Chain Triglyceride Oil Supplementation on Endurance Performance and Substrate Utilization in Healthy Populations: A Systematic Review |
| - | Review, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid